Shaoqin “Sarah” Gong collaborates on a new approach to target genetic mutations and develop a new therapy for restoring vision in children and adults.
A promising platform developed by the Saha Lab at WID advances the CRISPR genome editing field and could lead to effective treatments for many diseases.
WID’s Kris Saha was among UW–Madison researchers who have published a proof-of-concept method to correct an inherited form of macular degeneration that causes blindness, and that is currently untreatable.
WID’s Kris Saha spoke to Wisconsin Public Radio to answer questions about gene editing technology CRISPR in response to a question received by WHYsconsin.
The the MS Biotechnology program at UW and the Wisconsin Institute for Discovery are partnering to screen the documentary film “Human Nature”, an exploration of gene editing and its implications both biological and ethical.
WID’s Krishanu Saha and colleagues J. Benjamin Hurlbut and Sheila Jasanoff write in Scientific American about germ line editing and the need for more scientific and moral clarity.
An interdisciplinary pair of WID researchers has developed a new nanocapsule delivery method for delivering the CRISPR-Cas9 gene editing tool. The new system could be used for many types of gene therapies.
WID’s Randolph Ashton, assistant professor of biomedical engineering, is the new associate director for UW–Madison’s Stem Cell and Regenerative Medicine Center.